Search
Search
About
Log in
Join
Experiences with
Besremi
Posts
Communities
346 public posts
Filter results
Besremi: Efficacy and Safety in Different Age Groups
« In summary, after 24 months ropeginterferon induced higher hematological and molecular response rates and higher maintenance of response than HU in PV patients in the age groups < 60 years and ≥60 years, with the latter consisting of a majority of patients between 60 and 70 years of age and only a
« In summary, after 24 months ropeginterferon induced higher hematological and molecular response rates and higher maintenance of response than HU in PV patients in the age groups < 60 years and ≥60 years, with the latter consisting of a majority of patients between 60 and 70 years of age and only a
Manouche
in
MPN Voice
3 years ago
ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi®
«After two and a half years of arbitration proceedings concerning
BESREMi
® (Ropeginterferon alfa-2b), the decision by the ICC Arbitral Tribunal has now been made. In 2017 PharmaEssentia had attempted to terminate the contractual agreement with AOP Orphan.
«After two and a half years of arbitration proceedings concerning
BESREMi
® (Ropeginterferon alfa-2b), the decision by the ICC Arbitral Tribunal has now been made. In 2017 PharmaEssentia had attempted to terminate the contractual agreement with AOP Orphan.
Manouche
in
MPN Voice
4 years ago
ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi®
«We are relieved that the ICC ruling compensates AOP Orphan now for the delay in getting
BESREMi
® approved in the European Union, and the delay in bringing this important medication to the patients suffering from polycythaemia vera, a rare and chronic disease of the blood building cells", explains Dr
«We are relieved that the ICC ruling compensates AOP Orphan now for the delay in getting
BESREMi
® approved in the European Union, and the delay in bringing this important medication to the patients suffering from polycythaemia vera, a rare and chronic disease of the blood building cells", explains Dr
Manouche
in
MPN Voice
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Update 4.0
Likewise approval for
Besremi
. I imagine at some point I will opt for that as well. Of coarse, in the near-term, approval for the COVID vaccines would be really great. I will be getting my vaccine as soon as it is available.
Likewise approval for
Besremi
. I imagine at some point I will opt for that as well. Of coarse, in the near-term, approval for the COVID vaccines would be really great. I will be getting my vaccine as soon as it is available.
hunter5582
in
MPN Voice
4 years ago
Longterm Interferon treatment
The drug of choice I am inclined to initially try is pegylated interferon, either pegasys or
besremi
, if available in the US soon. I am calling on patients who have used and/or are still using interferon. How does/ did it work for you? What were your side effects and quality of life?
The drug of choice I am inclined to initially try is pegylated interferon, either pegasys or
besremi
, if available in the US soon. I am calling on patients who have used and/or are still using interferon. How does/ did it work for you? What were your side effects and quality of life?
Loooonglife
in
MPN Voice
4 years ago
BESREMi Ropeginterferon alfa-2b is available in Austria and Germany
After hearing very encouraging information regarding effectiveness of
BESREMi
Ropeginterferon alfa-2b from the doctor in my local clinic (based on clinical trial they run for several years) I checked the price in Austrian drug store.
After hearing very encouraging information regarding effectiveness of
BESREMi
Ropeginterferon alfa-2b from the doctor in my local clinic (based on clinical trial they run for several years) I checked the price in Austrian drug store.
Alexbits
in
MPN Voice
5 years ago
1
...
17
18
10
Filter results
Clear filters
Posted in
All communities
MPN Voice
344 results
Fight MPN
2 results
Sort by
Most Relevant
Newest